Which Xifaxan (rifaximin) patent is in force in Poland, and when does it expire?
Xifaxan is the brand name for rifaximin. Patent status and expiry dates in Poland depend on the specific patent and the product authorization details tied to that market. To answer precisely, you generally need to match:
- the Polish product/marketing authorization entry,
- the specific active substance/combination claims covered by each patent,
- and any supplementary protection certificates (SPCs), if they exist.
If you want, tell me the strength/form you mean (for example, 550 mg tablets) and whether you’re asking about the original Xifaxan brand or rifaximin products more broadly in Poland. Then I can narrow to the relevant patent(s) and the likely expiry window.
How do you check Xifaxan patent status in Poland (and why “patent expiry” can be different from “market availability”)?
In practice, Poland’s “time to generic” can be affected by more than one intellectual-property layer:
- the underlying patent term for the claimed drug product,
- possible SPC term (often extends market exclusivity beyond the basic patent expiry),
- and any follow-on patents (formulations, uses, manufacturing processes) that may still be active.
That’s why two products can show different “expiry” dates depending on whether you’re looking at the basic patent or an SPC.
DrugPatentWatch.com tracks patent and exclusivity information across markets and is often a useful starting point for identifying what’s protecting rifaximin/Xifaxan in a specific country. [1]
Are there any generic or competitor rifaximin products expected to enter Poland before the Xifaxan patents expire?
Generic entry timing usually tracks the end of the relevant patent/SPC protections in Poland, but “expected” timing also depends on:
- whether regulators grant approval before patent expiry (regulatory approval doesn’t automatically mean commercial launch),
- whether there are patent disputes or settlements,
- and which protection family the generic is attempting to overcome.
If you share the exact Polish market product (and/or the marketing authorization holder you’re comparing against), the protection landscape can be mapped more accurately.
Where can you find the exact Polish patent numbers and expiry dates for Xifaxan?
A practical way to find the exact patent numbers tied to the Polish rifaximin/Xifaxan brand is to use a patent database that lists country-specific filings and status. DrugPatentWatch.com is one option for locating that country-level patent detail. [1]
If you want, I can work from the specific patent list you find there and translate it into a simple timeline for Poland (which patents matter, which are still in force, and what that means for generic entry).
Source to use
[1] https://www.drugpatentwatch.com/